Treatment

Medical Fields suitable for Medical Travel in Japan

Medical technology in Japan for cancer screening and gastrointestinal diseases are known to be very strong, supported by good clinical statistics, i.e., high five year survival rate after the surgery (or radiology / chemotherapy) among the colon, rectal, stomach, and esophageal cancer patients as well as liver, lung, and larynx cancer (See Table below). 

Since Japanese health agency is notoriously slow and counter-productive when it comes to the approval of new drugs, Japan's hospitals and patients suffered for so long by the technology lag from the rest of the world. Ironically, these regulatory problems lead physicians to the innovations in the fields other than drug discoveries, i.e., in the surgical / laparoscopic, endoscopic, micro-catheter procedures, cell based immunotherapy / vaccinations, radiation (carbon ion and proton beam), and regenerative medicine (iPS cells, cell sheets).

Since the Japanese physicians had less options in chemotherapy, they had more opportunities in experiencing difficult surgeries, and tried the new treatments due to the low availability of drugs. Thus, many exotic and unique medical technologies emerged out of the isolations casued by the incompetence of Japanese health agency.

Site (Survival Rate:  %)

7 Cancer Registrates in Japan

US SEER Program Eurocare-3
Esophagus 25 14 10
Stomach 58 22 23
Colon 66 62 51
Rectum 63 63 48
Liver 17 7 7
Gallbladder 18 16 12
Pancreas 6 4 4
Larynx 77 65 62
Lung, bronchus 20 15 11

For initial considerations, we believe that there are seven options for overseas patients (healthy, or already diagnosed with cancer, heart disease, or other diseases).

  1. CT-PET / Medical Check-up on cancer or heart disease
  2. EMR / ESD examination / procedure on gastrointestinal cancer
  3. Micro-Catheter treatments on varicose veins (including the veins below the knee)
  4. Radiofrequency Ablation on lung, kidney or liver cancer combined with chemotherapy using optimal pathway for drug delivery
  5. Proton Beam Therapy / Carbon Ion Therapy
  6. Regenerative treatment on cardiomyopathy (myocardial infarction), blind (vision loss), esophagus cancer patients
  7. Cell based Immunotherapy (Autologous immune enhancement therapy) on advanced stage gastrointestinal cancer combined with chemotherapy

CT-PET is both low cost, and widely available in Japan. Essentially targeting other asians who may not have ready access to the facility, CT-PET check-up for cancer, heart disease, etc., may facilitate the early detection of cancer / polyps. For patients from US, Europe, or Middle East, the check-up may be the good initial trial for health to give the physician the careful analysis of their health conditions.

Both EMR and ESD was originally developed in Japan. EMR / ESD (endoscopic biopsy or polyp resection procedure on gastrointestinal tract) is the area that Japanese surgeons are leading the research at forefront. It is the minimally invasive endoscopic procedure that conserves organs / tissues, and patients can be discharged from the hospital in the same day or a week after the operations. It is usually applicable to early stage cancer / tumor, and improves the post-surgical health conditions such as loss of appetite, fever, chills, pains and life-long medication.

In japan, complex operations towards varicose veins below the knee are established with safey and high response rates. Various catheter and micro-catheter devices are extensively used, and some of them are only available in Japan.

Currently there are about 31 proton (or carbon ion) therapy facilities in the world, 8 of which is built in Japan. Proton Beam Therapy is much less invasive than other radiotherapy treatments, and can treat the cancer without incision of the body, and with much less side effects than X-ray treatments. Japan has invested in Proton beam therapy (PBT) / Carbon Ion Therapy infrastructure for a long time, and clinical level studies are numerous and thus well experienced with all kinds of localized tumors.

Cell based Immunotherapy (Autologous immune enhancement therapy) has been more frequently practised in Japan. Cancer Adoptive Cell Immunotherapy had obvious advantages in research and development since all the therapy materials are extracted from the patients, and considered natural as opposed to the chemical compounds of chemotherapy, thus escapes the significantly long years of drug approval processes. For that reason, japanese hospitals and cell processing research firms developed many exotic immunotherapy treatments tailored towards individual patient's genetic markers and immune class. Every year, citizens from USA and Europe comes to Japan to get cancer vaccinations only available in some japanese hospitals.

Gastrointestinal Procedures

Japan is traditionally known for the leading medical technology in gastrointestinal tract. Esophageal, gastric, colon, rectal, and liver cancers are particularly the focuses of elite surgeons in Japan. It is the rare field that Japanese surgeons outperform the US and European counterparts. Each year, a few informed patients from USA and Europe seek medications in the field of gastrointestinal tracts in Japan.

As illustrated in the table below, Japan has a better tracking record in the treatment of gastrointestinal cancer. It is however to be pointed out that the early detection of cancer and minimally invasive endoscopic procedures (EMR / ESD) allowing the conservation of organs / tissues were key drivers to decrease the mortality in Japan. 

 Procedures Description 

Endoscopic Ultrasound

Endoscopic ulatrasound is the screening method for pancreatic cancer, esophageal cancer, and gastric cancer. Pathogenic legions in the tract can be biopsied by a fine needle aspiration. This tecnology particularly promotes QoL of patients. 

Sentinel Lymph Node Biopsy

The sentinel lymph node is the first lymph node to which cancer is likely to spread from primary tumor. Node is extracted and examined to determine the presence of cancer. By using this technique, lymph node can possibly be preserved, while the tumor is removed. Generally less side effects than removing all lymph nodes.

Endoscopic Submucosal Dissection (ESD)

Japan has been leading the gastroendoscope technology since 1950s with the domestic medical device company like Olympus. Japanese surgeons are considered the best in the world for diagnosis and treatment of gastrointestinal related diseases. ESD is not usually avaialable outside Japan.

Natural orifice transluminal endoscopy (NOTES)

NOTES are still experimental, but possibly revolutionize the minimum invasive surgery techniques by eliminating abdominal incisions.

 Table 2: List of Gastrointestinal / Endoscopic Procedure

EMR / ESD,  Ultrasonograpy, NOTES are extensively operated in Japanese hospitals, and some patients, especially those with early stage cancer, may benefit from the procedures. Since those procedures are in rare clinical applications outside Japan, many Japanese surgeons are recognized world-class pioneers.

Patients or potential patients of gastrointestinal tract may consider a travel or a tour of a few days, a week, or longer to Japan to have medical examination of stomach, esophagus (Barrett's esophagus), colorectal (colon or rectal), and small bowel cancer, and remove the polyps / tumors at the same procedure. Outside Japan, surgeons usually have no choice other than removing the whole stomach, or digestive tract thereby causing loss of appetite, and swallowing pains, but in Japan, many surgeons can apply the special technique called EMR / ESD to preserve the stomach or digestive tract to allow the patient to live the normal life after the operation.

treatments

Endoscopic Submucosal Dissection (ESD) in Japan

Endoscopic Submucosal Dissection (ESD) is a minimally invasive treatment for early stage gastric / stomach / esophageal / colorectal cancer. It was pioneered in Japan in order to improve the malignant post-surgical health conditions such as loss of appetite, fevers, chills, pains and avoid the subsequent medications.

Regenerative Medicine on Dilated Cardiomyopathy, or Myocardial Infarction

Recent technological advances in cell sheets engineering extended to the pre-clinical trial of the treatment of heart disease patients often in need for the heart transplant.

Cardiac myoblast, or embryonic heart muscle cell has been proposed for the alternative treatment of the patients with dilated cardiomyopathy replacing the heart transplant treatment. However, its post-transplantation inflammatory responses made it difficult for the clinical applications.

Elimination of Barrett's Esophagus (BE) Dysplasia - Early Esophageal Cancer

Barrett's Esophagus (BE) refers to an abnormal change (metaplasia) in the cells of the lower esophagus. When damaged by the chronic stomach acid exposure, the cells turn from squamous epithelium (normal state) to columnar epithelium (metaplasia). Barrett's Esophagus patients may face the increased risk of esophageal cancer.

Progression of Barrett Esophagus into cancer is described as below:

Radiofrequency Ablation (RFA) on Liver cancer (Hepatocellular carcinoma)

Radiofrequency ablation is a promising medical procedure to remove liver or hepatocellular tumors using high frequency alternating current. A procedure is performed under image guidance, and considered to be highly technical field due to the underlying difficulty in spotting the tumors surrounded with neighboring organs, requiring the intervetionists well experienced with various types of tumors for both effective ablation and safety.

International Hospital Ranking

Cancer Adoptive Cell Immunotherapy in Japan

Cell based Immunotherapy (Autologous immune enhancement therapy) has been more frequently practised in Japan.Techniques to harvest the cells are extremely intricate and delicate processes. For the treatments to be rountinely available to the cancer patients apart from the clinical trials, advanced engineering cell reprocessing center must be available with good corroboration with the hospitals.

Since Japan made the Immuno-Cell Therapy to be a part of health care systems, the cell processing centers (CPCs) rapidly increased in the past decades. For the therapy of high complexity such as dendritic cell / autologous enhancement immunotherapy to be regularly practiced in the hospital, those CPCs were essential, and this explains why much of innovations in cell based cancer immunotherapy took place in Japan. 

Endoscopic Submucosal Dissection (ESD) \ Endoscopic Mucosal Resection (EMR) in Japan

Both EMR and ESD was originally developed in Japan. EMR / ESD (endoscopic biopsy or polyp resection procedure on gastrointestinal tract) is the area that Japanese surgeons are leading the research at forefront. It is the minimally invasive endoscopic procedure that conserves organs / tissues, and patients can be discharged from the hospital in the same day or a week after the operations. It is usually applicable to early stage cancer / tumor, and improves the post-surgical health conditions such as loss of appetite, fever, chills, pains and life-long medication.

Proton Beam Therapy

Currently there are about 31 proton (or carbon ion) therapy facilities in the world, 8 of which is built in Japan. Proton Beam Therapy is much less invasive than other radiotherapy treatments, and can treat the cancer without incision of the body, and with much less side effects than X-ray treatments. Japan has invested in Proton beam therapy (PBT) / Carbon Ion Therapy infrastructure for a long time, and clinical level studies are numerous and thus well experienced with all kinds of localized tumors.

Radiofrequency Ablation (RFA) on Liver cancer (Hepatocellular carcinoma)

Japan has been leading the RFA intervention technology for a long time, and the yearly number of RFA interventions in Japan currently exceeds that of United States and China. (See the Table below.) Survival rates for the patients undergoing the RFA are not different from those of surgery. But the surgery is harder to be operated multiple times, whereas the RFA is not restricted by the number of interventions or by the presence of Hepatitis.  For this reason, RFA becomes a standard treatment in Japan.

Yearly volume of RFA on Liver Cancer
Japan 34,000
US 14,000
China 9,500

Table: Yearly number of Radiofrequency ablation of Liver or hepatic tumors by country.

Regenerative Medicine on Dilated Cardiomyopathy, or Myocardial Infarction

Recent technological advances in cell sheets engineering extended to the pre-clinical trial of the treatment of heart disease patients often in need for the heart transplant.

Micro-Catheter treatments on varicose veins (including the veins below the knee)

In japan, complex operations towards varicose veins below the knee are established with safey and high response rates. Various catheter and micro-catheter devices are extensively used, and some of them are only available in Japan.

Cancer and Heart Disease Treatment in Japan  

Medical technology in Japan for cancer screening and gastrointestinal diseases are known to be very strong, supported by good clinical statistics, i.e., high five year survival rate after the surgery (or radiology / chemotherapy) among the colon, rectal, stomach, and esophageal cancer patients as well as liver, lung, and larynx cancer (See Table below). 

Since Japanese health agency is notoriously slow and counter-productive when it comes to the approval of new drugs, Japan's hospitals and patients suffered for so long by the technology lag from the rest of the world. Ironically, these regulatory problems lead physicians to the innovations in the fields other than drug discoveries, i.e., in the surgical / laparoscopic, endoscopic, micro-catheter procedures, cell based immunotherapy / vaccinations, radiation (carbon ion and proton beam), and regenerative medicine (iPS cells, cell sheets).

Since the Japanese physicians had less options in chemotherapy, they had more opportunities in experiencing difficult surgeries, and tried the new treatments due to the low availability of new drugs. Thus, many exotic and unique medical technologies emerged out of the isolations casued by the incompetence of Japanese health agency.

Site (Survival Rate:  %)

7 Cancer Registrates in Japan

US SEER Program Eurocare-3
Esophagus 25 14 10
Stomach 58 22 23
Colon 66 62 51
Rectum 63 63 48
Liver 17 7 7
Gallbladder 18 16 12
Pancreas 6 4 4
Larynx 77 65 62
Lung, bronchus 20 15 11